Tirzepatide denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Tirzepatide as "Experimental or Investigational"

An experimental/investigational denial means Cigna has determined that tirzepatide lacks sufficient evidence of clinical effectiveness for the specific indication prescribed, or that the indication falls outside what Cigna's coverage policy recognizes as established. This denial type is more common when tirzepatide is prescribed for an indication that received FDA approval more recently, or when it is prescribed for a condition where coverage policy has not yet been updated to reflect current FDA labeling.

This denial is challengeable: if the prescribed indication appears on the current FDA-approved label, the "experimental" characterization is factually incorrect as a matter of regulatory record. If the indication is off-label, the appeal requires a stronger evidentiary showing — your prescriber should reference the applicable professional society guideline and peer-reviewed clinical literature.

## Your Federal Appeal Rights

Under ACA §2719 and ERISA §503, experimental/investigational denials are subject to internal appeal and independent external review. File your internal appeal within 180 days of the denial notice. External review is available for approximately 4 months after final internal denial. Expedited review is available if clinical urgency applies.

## Concrete Appeal Steps

1. Confirm the prescribed indication and check whether it appears on the current FDA-approved prescribing label (DailyMed). 2. Request Cigna's experimental/investigational coverage policy for tirzepatide — this policy governs what evidence standard Cigna applies. 3. If the indication is FDA-approved: submit the FDA label and request immediate reconsideration on the basis that the denial is factually unsupported. 4. If the indication is off-label: your prescriber must compile peer-reviewed evidence and cite the applicable professional society guideline (e.g., the relevant ADA, AACE/ACE, or Obesity Medicine Association guidance) supporting the use. 5. File the internal appeal with the complete evidentiary package. 6. If denied, request external review — independent reviewers frequently overturn experimental denials for FDA-approved indications.

## Documentation to Gather

• Current FDA prescribing label for tirzepatide (print from DailyMed with retrieval date)
• Prescriber medical-necessity letter: explains the evidence base for the prescribed indication and cites the applicable guideline organization
• Peer-reviewed clinical literature (for off-label use): your prescriber selects and summarizes the relevant studies — do not rely on this document for specific statistics
• Diagnosis confirmation: chart notes, specialist assessments, diagnostic codes

## Criteria-Mapping Structure

Cigna's experimental policy will specify the evidence criteria it applies (e.g., FDA approval, peer-reviewed publication standard, guideline endorsement). Map each criterion: (1) FDA approval status for the indication — yes/no; (2) guideline organization endorsement — name the organization; (3) peer-reviewed literature — prescriber-selected citations. A concise table submitted with the appeal letter makes the reviewer's job straightforward and increases reversal rates.